Nivedita Namdev

This inventor holds 21 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Cancer Treatment. Top assignee: Arqule, Inc.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nivedita Namdev. Retrieved from https://idiyas.com/inventor/nivedita-namdev

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 5)

% Patents Active = 95.2

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 15)

Average Co-Inventor Count = 7.6

ph-index = 6

Forward Citations = 80(Granted Patents)

Company Filing History:

21 out of 104

Arqule, Inc.

patents

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Tetrahydropyranyl Compounds

Pyrrolopyrimidinone

Imidazopyridinyl

Pyrazolo-Pyrimidine

Cancer Treatment

RAF Inhibitors

Tricyclic Compounds

Pyrrolo-Aminopyrimidine

Dipyrido-Pyrimido-Diazepine

Indolo-Pyridinone

Dihydrobenzo-Isoquinoline

Pyrido-Azepine

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11020400 - Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof (2021-06-01),

2. 10933065 - Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof (2021-03-02),

3. 10245263 - Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof (2019-04-02),

4. 9630968 - Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof (2017-04-25),

5. 9012466 - Substituted tricyclic pyrazolo-pyrimidine compounds (2015-04-21),

6. 8962619 - Substituted imidazopyridinyl-aminopyridine compounds (2015-02-24),

7. 8906928 - Substituted pyrazolo-pyrrolo-pyridine-dione compounds (2014-12-09),

8. 8815854 - Substituted imidazopyridinyl compounds (2014-08-26),

9. 8609688 - Substituted imidazopyridinyl-aminopyridine compounds (2013-12-17),

10. 8580803 - Substituted pyrrolo-aminopyrimidine compounds (2013-11-12),

11. 8513292 - Compositions and methods for the treatment of cancer (2013-08-20),

12. 8501770 - Substituted imidazopyridinyl-aminopyridine compounds (2013-08-06),

13. 8410144 - Substituted indolo-pyridinone compounds (2013-04-02),

14. 8357694 - Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds (2013-01-22),

15. 8349827 - Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds (2013-01-08),

Title: Innovations of Nivedita Namdev: Pioneering Patents in Pharmaceuticals

Introduction

Nivedita Namdev, based in Westford, MA, is an innovative inventor renowned for her contributions to the pharmaceutical sector. With a remarkable total of 21 patents to her name, Nivedita has made significant strides in drug development, emphasizing the modulation of biological processes.

Latest Patents

Among her latest innovations is the patent for Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof. This application pertains to a unique compound that modulates the activity of BTK (Bruton’s tyrosine kinase), a crucial player in various diseases. The compound, along with its pharmaceutically acceptable salts, derivatives, and analogs, represents a significant advancement in therapeutic methods aimed at treating or preventing diseases where BTK operates.

Career Highlights

Nivedita has established herself as a pivotal figure in her field while working at Arqule, Inc. Her research and patenting activities reflect her dedication to innovative solutions that enhance medical treatments and patient outcomes.

Collaborations

Throughout her career, Nivedita has collaborated with esteemed colleagues, including Jean-Marc Lapierre and Manish Tandon. These partnerships underscore her commitment to teamwork and innovation, driving forward the frontiers of pharmaceutical research and development.

Conclusion

Nivedita Namdev's impact in the pharmaceutical industry through her numerous patents highlights her role as a pioneer in innovation. Her work not only contributes to scientific knowledge but also aims to improve lives by developing new therapeutic options.

Profile summary based on public USPTO records.